Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anaptysbio (ANAB) Revenue (2016 - 2025)

Anaptysbio filings provide 10 years of Revenue readings, the most recent being $75.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 200.0% year-over-year to $75.0 million, compared with a TTM value of $175.0 million through Dec 2025, up 201.0%, and an annual FY2025 reading of $234.6 million, up 157.01% over the prior year.
  • Revenue hit $75.0 million in Q4 2025 for Anaptysbio, up from $50.0 million in the prior quarter.
  • The five-year high for Revenue was $75.0 million in Q4 2025, with the low at $970000.0 in Q1 2022.
  • Median Revenue over the past 5 years was $9.5 million (2021), compared with a mean of $15.0 million.
  • The sharpest move saw Revenue tumbled 98.32% in 2021, then soared 422.49% in 2024.
  • Year by year, Revenue stood at $1.0 million in 2021, then soared by 394.56% to $5.0 million in 2022, then soared by 80.1% to $9.0 million in 2023, then skyrocketed by 177.62% to $25.0 million in 2024, then surged by 200.0% to $75.0 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $75.0 million, $50.0 million, and $22.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.